Domestic revenue of the Indian pharmaceutical industry grew steadily last fiscal, benefiting from the troika of higher volume, price hikes and new product launches.
Exports volume, especially to the regulated markets, rose as well on the back of shortages and closure of competitor facilities.
Operating profitability stayed healthy as input cost fell and operating leverage rose.
Growth over the medium term will be driven by sharper focus on affordability of blockbuster molecules that target complex diseases through biosimilars.
Improving prospects for contractual outsourcing amid greater focus on diversification strategies, such as China+1 and the proposed Biosecure Act will be supportive as well.
To boot, there is strong capital market and private equity interest in the sector.
What does all this mean for the revenue outlook, profitability and credit profiles of pharmaceutical companies this fiscal and beyond?
For answers, CRISIL Ratings is hosting a webinar at 3.00 pm on September 4, 2024, where its experts will delve into:
Demand drivers and outlook across markets
Growth opportunities, including for biosimilars and contractual offshoring opportunities
Profitability trends of CRISIL Ratings-rated pharmaceutical firms
Outlook on credit quality
The presentation will be followed by a panel discussion with sector experts and a Q&A session.
Disclaimer: This event and its content are intellectual property and confidential information of CRISIL. Any use of the same without written permission of CRISIL is illegal and hence punishable. Recording the webinar in any form in full or part or copying, altering, distributing or streaming the webinar is strictly prohibited and violation will attract legal action.
